The strong Phase 2 data de-risks the upcoming Study 306 readout and may drive near-term upside. Monitor for Phase 3 results in 1H 2027 and any competitive developments.
Price Chart
Executive Summary
Veradermics announced positive Phase 2 topline results for VDPHL01 in female pattern hair loss, showing mean TAHC increases of 22.7-23.3 hairs/cm² and ~90% PRO response at Month 6 with good safety. The data supports the upcoming Phase 2/3 Study 306 readout in 1H 2027, reinforcing VDPHL01's potential as the first FDA-approved oral treatment for the ~30M female patient market.
Key Facts
- Mean non-vellus TAHC increase of 22.7 hairs/cm² (QD) and 23.3 hairs/cm² (BID) at Month 6
- 88.9% (QD) and 90.0% (BID) of patients achieved improved/much improved on AAIRS PRO
- 63.2% reported improvement as early as Month 2; IGA showed 100% (QD) and 90% (BID) improved at Month 6
- No treatment-related SAEs or cardiac AESIs; most common AEs were hypertrichosis (21.4%) and peripheral edema (7.1%)
- Topline Phase 2/3 Study 306 results expected in 1H 2027
- First positive Phase 2 outcome for an oral PHL treatment in females in the U.S.
Financial Impact
Positive proof-of-concept for a potential blockbuster in a ~30M patient market; no financial data provided
Risk Factors
- Phase 3/ registrational trial failure (Study 306)
- Competition from existing off-label treatments or new entrants
- Regulatory delays or safety issues in larger trials
- High market expectations already priced in (92% analyst bullish)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001827635-26-000023 |
| Exhibit: exhibit991datarelease1.htm | 0001827635-26-000023 |
| Document: mane-20260715.htm | 0001827635-26-000023 |
| Document: 0001827635-26-000023-index-headers.html | 0001827635-26-000023 |
| Document: 0001827635-26-000023-index.html | 0001827635-26-000023 |
| Document: 0001827635-26-000023.txt | 0001827635-26-000023 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $122.28 $137.39 | ▲ +12.36% | ▲ +12.50% | $137.39 (+12.36%) |
Oct 13, 2026 13d ago | SC 13G | $116.26 $127.11 | ▲ +9.33% | ▲ +10.48% | $137.39 (+18.17%) |
Aug 21, 2026 9w ago | Insider Cluster | $98.46 $98.41 | ▲ +0.05% | ▲ +0.52% | $137.39 (−39.54%) |
Aug 20, 2026 9w ago | 3 | $102.82 $97.93 | ▼ −4.76% | ▼ −5.23% | $137.39 (+33.62%) |
Aug 18, 2026 9w ago | Insider Cluster | $111.23 $102.80 | ▼ −7.58% | ▼ −7.19% | $137.39 (+23.52%) |
Aug 11, 2026 10w ago | 8-K | $110.75 $111.31 | ▲ +0.51% | ▲ +0.91% | $137.39 (+24.05%) |
Aug 7, 2026 11w ago | S-1 | $110.75 $108.22 | ▲ +2.28% | ▲ +2.24% | $137.39 (−24.05%) |
Aug 7, 2026 11w ago | Institutional Cluster | $114.39 $112.71 | ▼ −1.47% | ▼ −1.87% | $137.39 (+20.11%) |
Jul 15, 2026 14w ago | 8-K | $123.70 $109.85 | ▼ −11.20% | ▼ −10.22% | $137.39 (+11.07%) |
May 12, 2026 23w ago | 8-K | $103.90 $100.38 | ▼ −3.39% | ▼ −3.47% | $137.39 (+32.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers